R&D channel feed

No­var­tis and Am­gen launch new Alzheimer's study

8 years ago
Discovery

Prize fight in Paris: Al­ny­lam and Io­n­is slug it out over PhI­II da­ta in prepa­ra­tion for a block­buster show­down

8 years ago

Sanofi scraps a PhII IL4/IL13 de­vel­op­ment pro­gram for lung scar­ring dis­ease

8 years ago

Dicer­na and Boehringer part­ner on RNAi treat­ment for NASH

8 years ago

AveX­is of­fers com­pelling rea­sons for a fast FDA OK for gene ther­a­py to treat spinal mus­cu­lar at­ro­phy in in­fants

8 years ago
Cell/Gene Tx

Agios spot­lights promis­ing da­ta for IDH1 drug, putting it on the path to FDA sub­mis­sion

8 years ago

As­traZeneca inks a car­dio drug de­vel­op­ment pact with mR­NA spe­cial­ist Mod­er­na

8 years ago
Pharma

#ASH17: No­var­tis’ 6-month Kym­ri­ah da­ta in DL­B­CL sets up a head-to-head fight with Gilead

8 years ago

#ASH17: The big los­er in CAR-T, Juno is mak­ing a bid to seize the fast lane to fron­trun­ner sta­tus

8 years ago

#ASH17: Blue­bird touts ear­ly signs that its new-and-im­proved sick­le cell gene ther­a­py is work­ing

8 years ago
Cell/Gene Tx

As­traZeneca’s asth­ma drug tralok­inum­ab goes 0 for 3 in PhI­II as 2 more tri­als flop

8 years ago

Stem­line wraps pos­i­tive piv­otal tri­al for its con­tro­ver­sial lead can­cer drug, clear­ing a path to the FDA

8 years ago

No­var­tis hus­tles along an­oth­er FDA ap­pli­ca­tion for CAR-T star, tack­ling Gilead head on

8 years ago

PhI­II deal­mak­ing fren­zy in i/o con­tin­ues as As­traZeneca fol­lows PA­CIF­IC with a new In­cyte IDO1 com­bo

8 years ago

Blood­ied Cel­gene posts promis­ing ozan­i­mod PhI­II MS da­ta, but is it re­al­ly a $6 bil­lion drug?

8 years ago

Brush­ing back biosims, a con­fi­dent Ab­b­Vie out­lines a block­buster win­ning streak ahead for Hu­mi­ra

8 years ago
Pharma

Ab­b­Vie boasts a PhI­II sweep for top pso­ri­a­sis con­tender risankizum­ab, but it has lots of com­pe­ti­tion

8 years ago

Am­gen buries the last big CETP drug, mark­ing the bit­ter end of a block­buster quest

8 years ago

The Med­i­cines Com­pa­ny brings out the ax, look­ing to jet­ti­son hun­dreds of jobs in top-to-bot­tom re­struc­tur­ing

8 years ago
Pharma

In­cyte grabs a new PD-1 check­point drug in $900M deal with Macro­Gen­ics

8 years ago

In an up­date, Gilead spot­lights top-line hits amid a mixed set of PhII da­ta for its $600M NASH drug

8 years ago

Tiny hep B drug com­bo study touts po­ten­tial of a ‘func­tion­al cure’ at lit­tle-known Replicor

8 years ago

Go­ing all in: Bio­gen com­mits an ex­tra $500M to Alzheimer’s block­buster hope­ful ad­u­canum­ab

8 years ago
Financing

In a set­back, Glob­al Blood Ther­a­peu­tics scraps IPF pro­gram as lead drug floun­ders in proof-of-con­cept tri­als

8 years ago
First page Previous page 287288289290291292293 Next page Last page
A service from the Financial Times